NasdaqGS:ZYMEBiotechs
Zymeworks (ZYME) EPS Loss In Q3 2025 Tests Bullish Profitability Narratives
Zymeworks (ZYME) has laid out a mixed set of FY 2025 numbers so far, with Q3 revenue of US$27.6 million and a basic EPS loss of US$0.26, alongside trailing twelve month revenue of US$134.5 million and a basic EPS loss of US$0.84. Over the past few quarters, revenue has ranged from US$16 million in Q3 2024 to US$48.7 million in Q2 2025, while basic EPS has moved between a loss of US$0.49 and a small profit of US$0.03. This sets up a story where investors are watching how quickly margins can...